Further Amendment to Duties Addressing the Synthetic Opioid Supply Chain in the People’s Republic of China as Applied to Low-Value Imports

The order directs Federal agencies to discontinue the duty-free de minimis treatment for products from the People's Republic of China (PRC), including Hong Kong, that are implicated in the synthetic opioid crisis. These products will now be subject to duties as described in the order, effective from May 2, 2025. The Department of Homeland Security, through U.S. Customs and Border Protection (CBP), is instructed to implement the necessary actions to enforce this order, including potential temporary suspension or amendment of regulations or notices. The United States International Trade Commission is also directed to adjust the Harmonized Tariff Schedule of the United States as needed to reflect these changes.